


BIOINFORMANT

The Global Exosome Market – Market Size, Forecast, Trials and Trends



**1ST AND ONLY MARKET RESEARCH FIRM TO
SPECIALIZE IN THE STEM CELL INDUSTRY**

TABLE OF CONTENTS

1.	REPORT OVERVIEW.....	20
1.1	Statement of this Report	22
1.2	Purpose of the Report	23
1.3	Executive Summary	25
2.	BIOLOGY AND MEDICAL FUNCTIONS OF EXOSOMES	27
2.1	Biogenesis of Exosomes	27
2.1.1	Uptake of Exosomes by Target Cell.....	28
2.2	The Structure of an Exosome	29
2.2.1	Molecular Contents of Exosomes.....	30
2.3	Types of Exosomes used in Exosome Industry	31
2.3.1	Natural Exosome Types	31
2.3.2	Engineered Exosomes	32
2.3.2.1	Engineered Exosomes by Type of Modification	32
2.4	Shift from cell therapy to Exosome Therapy	32
2.5	Expected Positive Developments in the Next Ten Years.....	34
2.6	Key Scientific Milestones in Medical Evolution of Exosomes	35
2.6.1	Key Scientific Milestones in Exosome Therapeutics	36
2.6.2	Key Scientific Milestones in Exosome Diagnostics	36
2.6.3	Key Scientific Milestones in Exosome-Based Aesthetics.....	37
2.6.4	Current Trends in Exosome Research	37
2.6.5	Current Trends in Exosome Patent Filings.....	38
2.6.6	Current Trends in Exosome-Based Clinical Trials	39
3.	EXOSOME RESEARCH & PUBLISHED PAPERS	40
3.1	Diagnostics & Liquid Biopsies	41
3.2	Targeted Drug Delivery Systems	41
3.3	Regenerative Medicine & Aesthetics	41
3.4	Explosive Volume of Published Papers on Exosomes	41
3.4.1	Published Papers on Exosome Diagnostics.....	42
3.4.2	Papers in PubMed.gov on Exosome-Based Targeted Delivery Systems	43
3.4.3	Papers on Therapeutic Applications of Exosomes.....	44
3.4.3.1	Higher Output of Published Papers on Exosome Therapeutics	46
3.4.4	Utilization of Exosome Purification Methods in Research	47
3.4.5	Distribution of Exosome Publications by Disease Type	48
3.4.6	Exosome-Based PubMed Publications by Cancer Type.....	49
3.4.7	Exosome Research Publications by Geography	50
3.5	Cost of Laboratory Research & Publishing one Exosome Research Paper	51
3.6	Leading Exosome Research Institutions.....	52
3.7	Collaborations between Research Institutions and Commercial Entities.....	53
3.8	Recent Trends in PubMed Publications on Exosomes	53
4.	EXOSOME PATENTS LANDSCAPE	55
4.1	Diagnostics & Liquid Biopsies	55
4.2	Drug Delivery Systems (DDS).....	55
4.3	Therapeutics & Regenerative Medicine	55
4.4	The Steady Growth in number of Patent Filings	56
4.4.1	Percent Share of Exosome Patent Filings by Domains of Innovation.....	57
4.5	Exosome Patent Filing Jurisdictions	58
4.6	Applicants of Filed Exosome Patents.....	59
4.7	Exosome Patent Inventors	62
4.8	Owners of Filed Exosome Patents.....	65
4.9	Legal Status of Filed Patents	68

4.10	Notable Recently Granted Patents.....	69
4.11	Licensing of Exosome Patents.....	70
4.12	Number of Exosome Patents Assigned to Leading Companies	71
4.13	Key Current Trends in Exosome Patent Filings	72
4.13.1	Shift from Lipid Nanoparticles (LNPs) to Exosomes	72
4.13.2	Explosion in Engineered Exosomes.....	72
4.13.3	Precision Diagnostics and Liquid Biopsies.....	72
4.13.4	Plant-Derived Exosomes in Cosmeceuticals.....	72
4.13.5	Manufacturing and "Product-by-Process" Claims	73
5.	CLINICAL TRIAL LANDSCAPE.....	74
5.1	Geographical Distribution of Exosome-Based Clinical Trials.....	74
5.2	Clinical Trials by Country	75
5.3	Clinical Trials by Phases	77
5.4	Funding for Clinical Trials.....	77
5.5	Exosome-Based Clinical Trials by Application.....	79
5.6	Major Diseases Addressed by Exosome-Based Clinical Trials	80
5.7	Clinical Trials Evaluating Exosomes as Cell-Free Therapeutics	81
5.8	Clinical Trials Evaluating Exosomes as Disease Diagnostics	81
5.9	Clinical Trials Evaluating Exosomes as Drug Delivery Vehicles.....	82
6.	DEALS & FUND-RAISING IN EXOSOME SPACE.....	84
6.1	Venture Capital (VC) Funding	84
6.1.1	PranaX Corporation.....	85
6.1.2	RION Vet	85
6.1.3	EverZom.....	86
6.1.4	Annie Aesthetic.....	86
6.1.5	Ciloa.....	86
6.1.6	ExoLab Italia.....	87
6.1.7	Esphera SynBio.....	87
6.1.8	Exogenus Therapeutics.....	87
6.1.9	EXO Biologics.....	87
6.1.10	INEXOPLAT	88
6.1.11	Mantra Bio	88
6.2	Partnership Deals in Exosome Sector, 2023-June 2026	88
6.2.1	ReNeuron Group Ltd. & Laverock Therapeutics	89
6.2.2	Esco Aster & Shine-On Biomedical.....	90
6.2.3	GENFIT & EverZom.....	90
6.2.4	RION & Lonza	90
6.2.5	Taiwan Exosome Company (TEC) & Toyota Holdings	90
6.2.6	HeXun Biosciences & JY BioMed	91
6.2.7	Exogenus Therapeutics & Lonza	91
6.2.8	Capricor Therapeutics & NIAID	91
6.2.9	Cytiva & RoosterBio	92
6.2.10	SomesTech & ConvEyXo	92
6.2.11	Sartorius & RoosterBio	92
6.3	Acquisition Deals in Exosome Sector	92
6.3.1	Marijuana, Inc.	93
6.3.2	Mdxhealth	93
6.3.3	ARCHIMED	93
6.3.4	ExoCoBio.....	94
6.3.5	Evox Therapeutics.....	94
6.4	Licensing Deals in Exosome Space, 2023-June 2026	94
6.4.1	Evox Therapeutics & Rett Syndrome Research Trust (RSRT)	95
6.4.2	Esco Aster & Shine-On Biomedical.....	95
6.4.3	Exousia Pro & University of Central Florida (UCF)	96

6.4.4	PranaX Corporation & MD Anderson Cancer Center	96
6.4.5	Brexogen & BMI Korea	96
6.4.6	HeXun Biosciences & JY BioMed	96
6.4.7	Elevai Labs & Yuva Bioscience	97
6.4.8	TOPPAN Inc. & Dai Nippon Toryo Co	97
6.4.9	Coya Therapeutics & Carnegie Mellon University (CMU)	97
6.4.10	ResearchDx & INOVIQ Limited	97
6.4.11	ATUM & Codiak Biosciences	98
6.5	Fund-Raising Trends in Exosome Space	98
6.5.1	Key Funding Trends	98
6.5.2	Notable Capital Inflows	99
7.	EXOSOMES ISOLATION / PURIFICATION TECHNOLOGIES	100
7.1	Ultracentrifugation (UC)	101
7.1.1	Differential Ultracentrifugation (DUC)	101
7.1.2	Density Gradient Ultracentrifugation (DGC)	102
7.2	Ultrafiltration (UF)	102
7.2.1	Tandem-Configured Ultrafiltration	103
7.2.2	Sequential Ultrafiltration	103
7.3	Size-Exclusion Chromatography (SEC)	104
7.4	Polymer Precipitation Method	104
7.5	Immunoaffinity Capture Method	105
7.6	Microfluidic Technique	106
7.6.1	Widely Utilized Exosome Isolation & Purification Kits	106
8.	UPSTREAM PROCESSING TECHNOLOGIES FOR EXOSOMES	108
8.1	Key Technologies & Methods	108
8.1.1	Stirred-Tank Bioreactor (STR)	109
8.1.2	Vertical-Heel Bioreactors (VWBRs)	110
8.1.2.1	PBS Biotech Vertical-Wheel® Bioreactors	110
8.1.2.2	Eppendorf DASbox® and BioBLU® Platforms	110
8.1.3	Hollow-Fiber Bioreactors (HFBRs)	111
8.1.3.1	Quantum Flex Cell Expansion System (Terumo BCT)	111
8.1.3.2	FiberCell Systems' HFBR	111
8.1.3.3	CelliGen BLU or FiberCell Systems' Cartridges (Cell Culture Company)	112
8.1.3.4	Xcellerex or WAVE Bioreactors (Cytiva)	112
8.2	Exosome-Depleted Media	112
8.2.1	Gibco Exosome-Depleted FBS (Thermo Fisher)	113
8.2.2	Exo-FBS (System Biosciences - SBI)	113
8.2.3	Exosome-Depleted Fetal Bovine Serum (Biowest)	114
8.3	Cell Engineering	114
8.3.1	Cargo Loading	114
8.3.1.2	Stable Transfection/Viral Transduction	115
8.3.2	Surface Modification	115
8.3.2.1	Genetic Engineering	116
8.3.2.2	Metabolic Labeling	116
8.3.3	Yield Enhancement	117
8.3.3.1	Key Strategies for Upstream Yield Enhancement	117
8.4	AIoT-Based Monitoring	117
8.5	Microfluidics	118
8.5.1	The Upstream Advantage of Microfluidics	118
9.	DOWNSTREAM PROCESSING TECHNOLOGIES FOR EXOSOMES	120
9.1	Harvest Clarification	120
9.2	Concentration & Purification	121
9.3	Post-Isolation Modifications	121

9.3.1	Surface Functionalization	122
9.3.2	Membrane Permeabilization and Loading	122
9.3.3	Membrane Fusion.....	122
9.4	Formulation	123
9.5	Storage.....	124
9.5.1	Cryopreservation (-80°C).....	124
9.5.2	Lyophilization (Freeze-Drying).....	124
10.	MAJOR PROPRIETARY EXOSOME MANUFACTURING PLATFORMS	125
10.1	ExoShell Platform.....	125
10.1.1	ExoShell Technology.....	125
10.1.2	Typical Applications.....	125
10.2	ExoDE & ExoEDIT Platforms.....	126
10.2.1	ExoDE & ExoEDIT Technologies	126
10.2.2	Primary Therapeutic Focus	126
10.3	StealthX platform.....	126
10.3.1	StealthX Technology	127
10.3.2	Primary Applications.....	127
10.4	EXPLOR and Pure-Exo Platforms	127
10.4.1	Technologies	128
10.4.2	Therapeutic Focus.....	128
10.5	DeliverEX® Platform	129
10.5.1	Technology	129
10.5.2	Core Therapeutic Programs	130
10.6	engEx™ Platform	130
10.6.1	Technology	130
10.6.2	Key Clinical Applications	130
10.7	Exopeptidase™ Platform	131
10.7.1	Technology	131
10.7.2	Therapeutic Focus.....	131
11.	EXOSOME ENGINEERING TECHNOLOGIES: AN OVERVIEW.....	133
11.1	Endogenous Loading (Cellular Modification)	133
11.1.1	Endogenous Exosome Loading Technologies	134
11.2	Exogenous Loading (Direct Modification)	135
11.2.1	Exogenous Loading Technologies	135
11.3	Surface Engineering (Targeting)	136
11.3.1	Molecules Anchored to Exosomes for Surface Modifications	136
11.3.2	Cost of Exosome Exterior Modifications.....	137
11.4	Exogenous Internal Loading of Exosomes	138
11.4.1	Technologies for Internal Loading	138
11.4.1.1	Electroporation.....	139
11.4.1.3	Extrusion	139
11.4.1.4	Saponin-Assisted Loading	139
11.4.1.5	Freeze-Thaw Cycling	140
11.4.1.6	Direct Incubation	140
11.5	Drugs Loaded Exogenously into Exosomes	140
11.5.1	Companies Developing Drug-Loaded Exosomes	141
11.5.2	Drug-Loaded Exosomes in the Ongoing Clinical Trials.....	142
11.5.3	Preclinical Studies using Drug-Loaded Exosomes	142
12.	THERAPEUTIC APPLICATIONS OF EXOSOMES	144
12.1	Exosome-Based Therapeutic Candidates in Phase III	146
12.1.1	Deramicecel (CAP-1002)	146
12.1.1.1	FDA Approval Status	147
12.1.2	ExoFlo (Direct Biologics)	147

12.1.2.1	Core Applications and Pipeline	147
12.1.2.2	Clinical Data and Efficacy	148
12.1.3	PEP Biologic (INTENT Biologics)	148
12.2	Core Therapeutic Exosome Platforms & Technologies	149
12.2.1	Cost of Developing a Therapeutic Exosome Platform	149
12.2.1.1	Typical Exosome Licensing Deal Structure	149
12.2.2	Examples of Therapeutic Exosome Platforms	150
12.2.2.1	ExoEdit® Platform	150
12.2.2.2	DeliverEX™ Platform	150
12.2.2.3	StealthX™ Platform	150
12.2.2.4	ExoFlo™ Platform.....	151
12.2.2.5	AGLE-102 Platform.....	151
12.2.2.6	AB126 Platform.....	151
12.2.2.7	BG-Platform	151
12.2.2.8	Microalgae Extracellular Vesicles (MEVs)	152
12.2.2.9	Hybridosome® Platform.....	152
12.2.2.10	EVENGI Platform	152
12.2.2.11	XoGlo® Platform	152
12.2.2.12	Triple-A platform	153
12.2.2.13	REGENT® platform	153
12.2.2.14	EXPLOR® Platform	153
12.2.2.15	Exo-Target® Platform	153
12.2.2.16	Kuragenx Platform	154
12.2.2.17	EVerGel™ Platform	154
12.2.2.18	Eviv Platform	154
12.2.2.19	EVOGEX platform.....	154
12.3	Cost of Developing an Exosome-Based Therapeutic	155
12.3.1	Better Clinical Utility of Exosomes.....	156
13.	DIAGNOSTIC APPLICATIONS OF EXOSOMES	157
13.1	Advantages of Exosome-Based Diagnostic Tests	157
13.2	Major Indications Focused by Developers of Exosome Diagnostics	158
13.2.1	Oncology.....	158
13.2.2	Neurology & Neurodegenerative Diseases	158
13.2.3	Other Major Indications	159
13.3	Major Milestones Achieved in Exosome-Based Diagnostic Sector	160
13.3.1	High-Sensitivity Technologies	160
13.3.2	Commercialization of Exosome-Based Tests.....	160
13.3.3	Cost of Developing an Exosome-Based Diagnostic.....	161
13.3.4	R&D and Biomarker Discovery.....	162
13.3.5	Analytical Validation & Assay Optimization	162
13.3.6	Clinical Trials & Validation	162
13.3.7	Regulatory & Commercialization	163
13.4	Diagnostic Exosome-Based Late-Stage Clinical Pipeline.....	163
13.4.1	Key Pipeline Tests & Companies	163
13.5	Exosome-Based Diagnostics in Development by Indication.....	164
13.5.1	Companies Developing Exosome-Based Diagnostics for Lung Cancer	164
13.5.2	Companies Developing Exosome Diagnostics for Pancreatic Cancer	165
13.5.3	Companies Developing Exosome-Based Diagnostics for Ovarian Cancer	166
13.5.4	Companies Developing Exosome Diagnostics for Cardiovascular Diseases ..	166
13.5.5	Companies Developing Exosome Diagnostics for Urology Indications	167
13.5.6	Companies Developing Exosome Diagnostics for Organ Transplantation	168
13.5.7	Companies Developing Exosome-Based Diagnostics for Pregnancy	168
13.6	Exosome Diagnostics Approaching Market Readiness	169
13.7	Future of Exosome Diagnostic Industry	170

14.	APPLICATIONS OF EXOSOMES IN MEDICAL AESTHETICS	171
14.1	Exosomes in Skin Rejuvenation & Anti-Aging	171
14.1.1	Exosome Skin Rejuvenation & Anti-Aging Products in the Market	172
14.1.1.1	Professional & Clinical-Grade Aesthetic Exosome Products	172
14.1.1.2	At-Home "Exosome-Inspired" Skincare Products.....	173
14.2	Exosome-Based Hair Regeneration.....	174
14.3	Exosome-Based Scar Reduction	174
14.4	Exosome-Based Pigmentation Regulation	175
14.5	Exosome-Based Post-Procedure Recovery Products	176
14.6	Percent Share Utilization of Medical Aesthetic Products by Type	177
14.7	Primary Sources of Exosomes for Medical Aesthetic Companies	177
14.8	Countries with the largest Utilization of Medical Aesthetics	178
14.9	More Examples of Exosome-Based Medical Aesthetics	179
14.9.1	Exosome-Based Serums.....	179
14.9.2	Exosome-Based Masks.....	179
14.9.3	Exosome-Based Creams.....	180
14.9.4	Exosome-Based Lotions.....	180
14.9.5	Exosome-Based Haircare Aesthetics.....	180
14.9.6	Human-Derived Exosome-Based Aesthetics	181
14.9.7	Plant-Derived Exosome-Based Aesthetics.....	181
14.9.8	Animal-Derived Exosome-Based Aesthetics.....	182
15.	MARKET ANALYSIS	183
15.1	Market for Exosome Research Products	184
15.2	Exosome Development & Manufacturing Market.....	189
15.2.1	Global Market for Exosome Development & Manufacturing Services	191
15.3	Global Market for Exosome Diagnostics	194
15.4	Market for Exosome-Based Medical Aesthetics	197
15.5	Global Market for Exosome-Based Aesthetics by Geography, 2006-2034	201
15.5.1	Percent Share of Exosome-Based Skincare Products by Type.....	202
15.5.2	Percent Share of Exosome-Based Skincare Products by Cell Source	204
15.6	Global Market for Exosome-Based Therapeutics	205
15.7	Global Market for "Ready-To-Use" Exosomes.....	208
15.8	The Overall Global Market for Exosome-Based Products	211
16	EXOSOME COMPANY PROFILES	215
16.1	Abcam plc.....	219
16.1.1	Core Exosome Product Portfolio	219
16.1.1.1	Immunophenotyping & Marker Detection	219
16.1.1.2	Specific Isolation Kits	219
16.1.1.3	Quantification & Assay Platforms	220
16.2	AcouSort AB.....	220
16.2.1	Acoustofluidic Separation	220
16.2.2	The AcouSome Project.....	221
16.2.3	AcouTrap Platform.....	221
16.3	Aegle Therapeutics	222
16.3.2	Clinical Milestones.....	222
16.4	Aethlon Medical, Inc.	223
16.4.1	The Hemopurifier.....	223
16.4.2	Oncology Clinical Trials	223
16.5	AGS Therapeutics.....	224
16.5.1	Clinical Programs	224
16.6	Akrivis Health Care Pvt., Ltd.	225
16.6.1	Core Business & Products.....	225
16.6.1.1	SynExo.....	225
16.6.1.2	TympanoSeal™	226

16.7	AnswerBio	226
16.7.1	Technology	226
16.8	AnteAGE	227
16.8.1	Exosome-Based Products	227
16.8.1.1	AnteAGE MDX® Exosome Solution	227
16.8.1.2	AnteAGE Biosomes™	228
16.9	Aposcience AG.....	228
16.9.1	APOSEC™	228
16.10	Aruna Bio, Inc.	229
16.10.1	Lead Therapeutic Candidate (AB-126)	229
16.11	Ascension Medical Biotechnology Co., Ltd. (AM BioTech).....	231
16.11.1	Bio-Pulsed Platform	231
16.11.2	ExoGiov	231
16.11.3	Key Applications & Products	232
16.12	BioCat GmbH	232
16.12.1	Key Focus Areas & Solutions.....	232
16.13	BioFluidica.....	233
16.13.1	LiquidScan platform	233
16.13.2	Core Technology & Workflow.....	234
16.13.3	Key Clinical Applications	234
16.13.4	Advantages	234
16.14	Biorbyt, Ltd.	235
16.15	Bioscience Institute	236
16.15.1	Core Areas of Operation	236
16.15.2	Key Facilities	236
16.15.3	Exosome Services	237
16.16	Biosynth International, Inc.	237
16.16.1	Core Exosome Offerings.....	238
16.17	Bio-Techne Corporation	238
16.17.1	Key facets of Bio-Techne's exosome portfolio	238
16.18	BioXtek	239
16.18.1	Manufacturing & Facilities	239
16.18.2	Product Portfolio.....	239
16.18.3	Strategic Partnerships	240
16.19	BreStem Therapeutics, Inc.	240
16.19.1	Core Technologies and Pipeline	240
16.20	Capricor Therapeutics.....	241
16.20.1	StealthX™ Exosome Platform.....	241
16.20.2	Capricor's Exosome-Based Clinical Programs	241
16.21	Carmine Therapeutics.....	242
16.21.1	REGENT® Platform	242
16.21.2	Industry Context and Therapeutic Focus	243
16.21.3	Pipeline and Commercial Milestones.....	243
16.22	Cellarcus Biosciences Inc.	244
16.22.1	Key Highlights	244
16.23	Cells for Cells	245
16.23.1	Cellistem®OA.....	245
16.24	Ciloa SAS	246
16.24.1	Core Technology Platform	246
16.24.2	Therapeutic Pipeline & Applications	246
16.25	ConveyXO	247
16.25.1	Exo-Harvest Technology	247
16.25.2	XomeXBio (RNA loading) Technology	248
16.25.3	Clinical Applications	248
16.25.3.1	Clinical Programs.....	248
16.26	Coya Therapeutics, Inc.	249

16.26.1	Exosome Platform Focus	249
16.26.2	Nanoengineering and Exosome-Polymer Hybrids (EPHs)	250
16.27	Craif, Inc.	250
16.27.1	Core Technology & Platform	250
16.27.2	Key Products and Applications	251
16.27.3	Global Expansion & Clinical Trials	251
16.28	Creative Bioarray	252
16.28.1	Key Exosome Services	252
16.28.2	Exosome Products Offered	253
16.28.3	Primary Context & Use Cases	253
16.29	Creative Biolabs	254
16.29.1	Core Exosome Services	254
16.29.2	Therapeutic & Clinical Applications	254
16.30	Creative Biostructure	255
16.30.1	Key Service & Product Areas	255
16.30.2	Primary Applications	255
16.31	Creative Medical Technology Holdings	256
16.31.1	Exosome-Focused Platforms and IP	256
16.32	Creative Proteomics	257
16.32.1	Key Exosome Services	257
16.33	CUSABIO Technology LLC	258
16.33.1	Exosome-Specific Products & Services	258
16.34	Danaher Corporation	259
16.34.1	Key Operating Companies & Their Contributions	259
16.34.2	Applications in Research and Medicine	259
16.35	Diadem Biotherapeutics	260
16.35.1	DECOSTAR™	260
16.36	Direct Biologics	261
16.36.1	Clinical Programs	261
16.37	DynaCord Stem Cell Research	262
16.37.1	Core Exosome Focus & Services	262
16.37.2	Dynacord's Core R&D Focus	262
16.38	Elevai Skincare	263
16.38.1	Core Technology & Science	263
16.38.2	Key Product Lines	263
16.38.2.1	ELEVAI enfinity™	264
16.38.2.2	ELEVAI empower™	264
16.39	Entelexo Biotherapeutics	265
16.39.1	Core Technology & Pipeline	265
16.40	EriVan Bio	266
16.40.1	Core Offerings & Capabilities	266
16.41	Esphera SynBio Inc.	267
16.41.1	Core Technology & Pipeline	267
16.42	Ever Supreme Bio Technology Co., Ltd.	268
16.42.1	EXO 001 Platform	268
16.42.2	The αDAT-EV Platform	269
16.43	EverZom	269
16.43.1	EverGel	270
16.43.2	EViv	270
16.44	Evolutionary Biologics (EOBIO)	271
16.44.1	Key Products & Applications	271
16.44.1.1	EVO Hybrid	271
16.44.1.2	EVO ELIXIR	272
16.44.1.3	EVO GRO	272
16.44.1.4	EXO PERIO	272
16.45	Evora Biosciences	273

16.45.1	EVO-003	273
16.45.2	EVOGEX	273
16.46	Evov Therapeutics Limited	274
16.46.1	ExoEdit Platform	274
16.46.2	Core Pipeline Programs	275
16.47	EV Therapeutics	276
16.47.1	mTEV Immunotherapy Platform	276
16.48	EXO Biologics SA	277
16.48.1	ExoPulse Technology	277
16.49	ExoCan Healthcare	279
16.49.1	ExoEnrich™	279
16.50	Exocel Bio	280
16.50.1	The Exovex™ Serum Line	280
16.51	Exogenus Therapeutics SA	281
16.51.1	EXO-101	282
16.52	Exokeryx, Inc.	283
16.52.1	Core Technology & Products	283
16.52.2	Demeter EVPrep	283
16.52.3	ExoScan	284
16.53	ExoLab Italia	284
16.53.1	Key Corporate Highlights	284
16.54	EXORPHIA, Inc.	285
16.54.1	Core Platforms & Pipeline	285
16.55	Exosome Plus	286
16.55.1	ExoThera Platform	286
16.56	Exosome Sciences, Inc.	287
16.56.1	TauSome™ Biomarker	287
16.57	Exosomics S.p.A.	288
16.57.1	Technologies	288
16.57.1.1	SeleCTEV™ DNA Enrichment kit	288
16.57.1.2	SoRTEV platform	289
16.58	ExoStemTech Co., Ltd	290
16.58.1	CARTISOME®	290
16.58.2	EST-T-EXO	290
16.58.3	HEPATOSOME®	291
16.58.4	HYPOXISOME®	291
16.59	ExoTop Theragnostics, Inc.	291
16.59.1	Key Operations & Services	291
16.60	ExoVectory B.V.	292
16.61	ExoXpert	292
16.61.1	ExoPulse Platform	293
16.61.2	Services Available	293
16.62	ExSURE	294
16.62.1	ExoDS Platform	294
16.62.2	Commercial Products	295
16.63	FYR Bio	295
16.63.1	EV-Omics (EVO) Platform Technology	295
16.63.1.1	Clinical & BioPharma Applications	296
16.63.2	SPARCS™ Technology	296
16.63.2.1	Core Applications and Impact	297
16.64	GBI Biomanufacturing	297
16.64.1	GBI's Role in Exosome Development	297
16.65	HansaBioMed Life Sciences, Ltd.	298
16.65.1	Core Offerings & Technology	298
16.66	Hexun Life Science Co., Ltd.	299
16.66.1	Core Business and Pipeline	299

16.67	Hilltop Bio	300
16.67.1	Regenaflex-RT	300
16.67.1.1	Primary Indications and Uses	300
16.67.2	Strydaflex and Strydaflex-K9.....	301
16.67.3	Strydaflex (Equine).....	301
16.67.4	Strydaflex-K9 (Canine).....	301
16.67.5	Regenaflex-M	301
16.68	Human Continuum Inc.	302
16.68.1	Core Focus Areas	302
16.69	ILIAS Biologics	303
16.69.1	EXPLOR® Technology	303
16.69.2	Exo-Target® Technology	303
16.69.3	Lead Product Candidate	304
16.69.3.1	Clinical Status	304
16.70	INEXOPLAT Inc.	305
16.70.1	Core Focus & Pipeline	305
16.71	InnoCan Pharma	306
16.71.1	CLX Platform	306
16.72	Innovex Therapeutics, SL	307
16.72.1	Key Research & Pipeline	307
16.73	INOVIQ	308
16.73.1	NETs technology	308
16.73.1.1	Clinical Applications	308
16.73.2	SubB2M Platform	309
16.73.2.1	Applications and Clinical Focus	309
16.73.3	Clinical Programs	309
16.74	INTENT Biologics	311
16.74.1	Products	311
16.75	Irazu Oncology, LLC	312
16.75.1	Outer Membrane Vesicle Platform	312
16.75.2	Lead Therapeutic Candidates	312
16.76	Izon Science Limited	313
16.76.1	Solutions Provided by Izon.....	313
16.76.1.1	Nanoparticle Analysis Solution	313
16.76.1.2	Isolation & Separation Solutions.....	314
16.76.2	Main Product Lines	314
16.76.2.1	Nanoparticle Analysis Instruments	314
16.76.2.2	Isolation & Separation Systems.....	315
16.77	JY BioMed	315
16.77.1	Exosome Platforms & R&D	315
16.77.2	Pipeline & Technology	316
16.78	Kimera Labs	317
16.78.1	Vive	317
16.78.2	Luxir & Luxir +	317
16.79	LongEVity Bioscience	318
16.79.1	Core Focus & Product Brands	318
16.79.1.1	PHYTOXOME	318
16.79.1.2	JUVEV EXOGLOW.....	319
16.79.2	Nutritional Supplements	319
16.80	Lonza Group AG	320
16.80.1	Core Capabilities & Technologies	320
16.81	MDxHealth.....	321
16.81.1	SelectMDx.....	321
16.81.1.1	Coverage and Insurance	322
16.81.2	ConfirmMDx	322
16.82	Mercury Bio, Inc.	323

16.82.1	Technology	323
16.83	Mercy BioAnalytics, Inc.	324
16.83.1	The Mercy Halo™ Platform	324
16.83.1.1	Clinical Focus and Progress	325
16.83.2	The Evident Test	325
16.83.2.1	Clinical Efficacy & Current Status	325
16.84	Microgen Ltd.....	326
16.84.1	Secretomix®.....	326
16.84.2	Core Pipeline & Indications	326
16.85	Microgentas, Inc.	327
16.85.1	Business Divisions	327
16.85.1.1	EV Isolation Services	327
16.85.1.2	EV Characterization Services	328
16.85.2	Product Line Up	328
16.85.2.1	ExoPAS™	328
16.85.2.2	ExoCAS-2™	328
16.85.2.3	ExoFilter™	329
16.85.2.4	ExoTFF™	329
16.85.2.5	miRQuick™	329
16.85.2.6	ExoSCAN™	329
16.85.2.7	gTx	330
16.85.2.8	JUVEV™	330
16.86	Miltenyi Biotec	330
16.86.1	Core Exosome Technologies	330
16.86.1.1	Target Applications	331
16.87	MiRNA Scientific.....	331
16.87.1	Core Platform & Products	332
16.88	Mursula Bio	332
16.88.1	EvoLiver®.....	332
16.89	Nano24 (formerly OBCTCD24)	333
16.89.1	Core Technology	333
16.89.2	Clinical Focus & Pipeline.....	334
16.90	NanoSomix, Inc.	334
16.90.1	Technology.....	334
16.91	Neucore Bio.....	335
16.91.1	Technology & Research.....	335
16.92	NeuroDex	336
16.92.1	Core Technology & Pipeline.....	336
16.92.2	Proprietary ExoSort Platform	337
16.92.2.1	Key Advantages & Capabilities.....	337
16.93	NeuroSense Therapeutics	338
16.93.1	Exosome-Based Research & Partnerships.....	338
16.94	Norgen Biotek Corporation.....	339
16.94.1	Core Exosome Technologies	339
16.94.2	Product Portfolio.....	339
16.95	Novaxomx GmbH	340
16.96	Novus Biologicals, LLC	341
16.96.1	Key Exosome Research Tools.....	341
16.96.2	Target Research Areas	341
16.97	Nucelion Therapeutics Private Limited	342
16.97.1	Nucelion in the Exosome Context	342
16.98	NX Prenatal, Inc.	343
16.98.1	NeXosome Platform	343
16.98.2	Core Clinical Applications	343
16.99	Oasis Diagnostics® Corporation	344
16.99.1	Pure•SAL™	344

16.99.2	RNAPro•SAL™	344
16.100	OmniSpirant Therapeutics	345
16.100.1	OmniSomes Platform	345
16.100.1.1	Key Features and Capabilities	345
16.100.2	Pipeline Indications	346
16.101	OncoXome, Inc.	347
16.102	Paracrine Therapeutics Pte, Ltd.	347
16.103	PranaX Corporation	348
16.103.1	Core Technology	348
16.104	Prediction Biosciences	349
16.105	QIAGEN N.V.	349
16.105.1	Core Exosome Capabilities	349
16.106	Regen Suppliers	350
16.106.1	Product Portfolio & Services	350
16.107	Regenerelle LLC	351
16.108	ReNeuron	352
16.108.1	CustomEX™ Technology	352
16.109	Resilielle Cosmetics LLC	353
16.109.1	Product Offerings	353
16.110	Rhythm Biotherapeutics	354
16.110.1	RBex	354
16.111	RION	355
16.111.1	Purified Exosome Product (PEP™)	355
16.112	Rosetta Exosome Co., Ltd.	356
16.112.1	ExoLutE®	356
16.113	RoosterBio, Inc.	357
16.113.1	Core Focus	357
16.113.2	Platforms & Partnerships	357
16.113.3	Services	358
16.114	ShiftBIO	359
16.114.1	Programmable NNP Platform	359
16.115	Shine-On Biomedical Co., Ltd.	360
16.115.1	Core Technology & Pipeline	360
16.115.1.1	Targeted Exosome Platforms (SOB Series)	360
16.115.1.2	Trispecific Antibody Platforms (SOA Series)	361
16.116	Somestech Biotechnology Co., Ltd.	362
16.116.1	Core Platforms & Technology	362
16.117	Souvie Bidelivery, LLC	363
16.117.1	Technology & Focus	363
16.118	Stemcell Medicine Ltd.	364
16.118.1	Exosome Focus & Therapeutic Applications	364
16.119	STRM.BIO	365
16.119.1	Core Technology & Platform	365
16.119.2	Therapeutic Pipeline & Focus	366
16.120	System Biosciences (SBI)	366
16.120.1	Core Exosome Focus Area	366
16.120.2	Value to the Scientific Community	367
16.121	Takara Bio, Inc.	367
16.121.1	Exosome-Specific Product Portfolio	367
16.121.2	Isolation & Purification Kits	368
16.121.3	Specialized Stem Cell Media	368
16.121.4	Downstream Multiomics Integration	368
16.122	Terasom Ltd.	369
16.122.1	Core Focus & Technology	369
16.123	Thermo Fisher Scientific	370
16.123.1	Core Exosome Workflow Solutions	370

16.123.2	Applications & Strategic Focus	370
16.124	The Tiny Cargo Company	371
16.124.1	Key Advantages	371
16.125	TransGen Biotech Co., Ltd.....	372
16.125.1	TransExo® PS Exosome Isolation Kit.....	372
16.125.2	TransExo® Cell Media Exosome Kit.....	372
16.126	Tymora Analytical Operations	373
15.126.1	EVtrap	373
16.126.2	pIMAGO & PolyMAC	373
16.127	Unchained Labs	374
16.127.1	The Leprechaun Platform.....	374
16.128	Unicyte AG	375
16.128.1	Human Liver Stem Cells (HLSCs)	375
16.128.1.1	Key Characteristics and Therapeutic Applications	375
16.128.2	Functional Pancreatic Islets	376
16.128.2.1	Core Technology.....	376
16.129	Urvogelbio Pvt. Ltd.....	377
16.129.1	Research & Technology Focus	377
16.130	Versatope Therapeutics, Inc.	378
16.130.1	Versatope's Exosome	378
16.130.2	Current Pipeline & Developments	379
16.131	VesiCURE Therapeutics	379
16.131.1	modEXO Platform	379
16.131.2	dilEVry Platform.....	380
16.131.2.1	Key Capabilities of the dilEVry Platform	380
16.132	VivaZome Therapeutics Pty Ltd	381
16.132.1	Core Technologies & Therapeutics.....	381
16.133	Xosomix.....	382
16.133.1	Core Technology & Focus.....	382
16.134	XOStem, Inc.	383
16.134.1	Core Focus & Technology.....	383
16.135	ZEO ScientifiX, Inc.	384
16.135.1	Key Products & Pipeline.....	384

INDEX OF FIGURES

FIGURE 2.1: Biogenesis of Exosomes	27
FIGURE 2.2: Uptake of Exosomes by Target Cell	28
FIGURE 2.3: Structure of an Exosome	29
FIGURE 3.1: The Growth in Volume of Published Papers on Exosomes, 2010-2025	42
FIGURE 3.2: Number of PubMed.gov Published on Diagnostic Exosomes, 2010-2025.....	43
FIGURE 3.3: Number Papers on Exosome's Application in Targeted Drug Delivery	44
FIGURE 3.4: Number of Published Papers on Therapeutic Application of Exosomes	45
FIGURE 3.5: Higher Output of Published Papers on Exosome Therapeutics	46
FIGURE 3.6: Percent Share of Exosome Cargo Loading Technologies	47
FIGURE 3.7: Percent Share of Exosome Purification Technologies in Research	48
FIGURE 3.8: Distribution of Exosome Publications by Disease Type	49
FIGURE 3.9: Exosome-Based PubMed Publications by Cancer Type	50
FIGURE 3.10: The Geographical Split of Exosome Publications.....	51
FIGURE 4.1: The Steady Growth in Number of Patent Filings, 2000-2026	56
FIGURE 4.2: Percent Share of Exosome Patent Filings by Primary Domains of Innovation.....	57
FIGURE 5.1: Percent Share of Clinical Trials by Geography	75
FIGURE 5.2: Exosome-Based Clinical Trials by Application	79

FIGURE 5.3: Percent Share of Diseases Addressed by Exosome-Based Clinical Trials.....	80
FIGURE 13.1: Major Indications Focused for Diagnosis.....	159
FIGURE 13.2: Share of Disease Indications Focused on by Exosome Diagnostics	164
FIGURE 14.1: Percent Share Utilization of Medical Aesthetic Products by Type.....	177
FIGURE 14.2: Percent Share of Exosome-Based Aesthetic Utilization by Geography	178
FIGURE 15.1: Estimated Market for Exosome Research Products, 2026-2034	188
FIGURE 15.2: Market for Exosome Development & Manufacturing Services, 2026-2035.....	193
FIGURE 15.3: Global Exosome Diagnostics Market by Geography, 2026-2034.....	197
FIGURE 15.4: Global Market for Exosome-Based Aesthetics by Product Type, 2026-2034	200
FIGURE 15.5: Global Market for Exosome-Based Aesthetics by Geography, 2026-2034	202
FIGURE 15.6: Percent Share of Exosome-Based Skincare Products by Type	203
FIGURE 15.7: Percent Share of Exosome-Based Skincare Products by Cell Source	204
FIGURE 15.8: Estimated Market for Exosome-Based Therapeutics, 2026-2034.....	208
FIGURE 15.9: Global Market for Ready-To-Use Exosomes, 2026-2034.....	210
FIGURE 15.10: Global Market for all its Market Segments by Geography, 2026-2034.....	214

INDEX OF TABLES

TABLE 2.1: Molecular Contents of Exosomes	31
TABLE 2.2: Companies Shifting from Cell Therapy to Exosome Therapy	33
TABLE 2.3: Key Scientific Milestones in the Medical Evolution of Exosomes	35
TABLE 2.4: Key Scientific Milestones in Exosome Therapeutics	36
TABLE 2.5: Key Scientific Milestones in Exosome Diagnostics.....	37
TABLE 2.6: Key Scientific Milestones in Exosome-Based Aesthetics	37
TABLE 2.7: Current Trends in Exosome Research.....	38
TABLE 2.8: Current Trends in Exosome Patent Filings	38
TABLE 2.9: Current Trends in Exosome-Based Clinical Trials	39
TABLE 3.1: Cost of Research & Publishing One Exosome Research Paper	52
TABLE 3.2: Leading Exosome Research Institutions.....	52
TABLE 3.3: Collaborations between Research Institutions and Commercial Entities	53
TABLE 4.1: Exosome Patent Filing Jurisdictions	58
TABLE 4.1: (CONTINUED)	59
TABLE 4.2: Exosome Patent Applicants as of June 2026	60
TABLE 4.2: (CONTINUED)	61
TABLE 4.2: (CONTINUED)	62
TABLE 4.3: Exosome Patent Inventors as of June 2026	63
TABLE 4.3: (CONTINUED)	64
TABLE 4.3: (CONTINUED)	65
TABLE 4.4: Owners of Filed Exosome Patents as of June 2026.....	66
TABLE 4.4: (CONTINUED)	67
TABLE 4.4: (CONTINUED)	68
TABLE 4.5: Legal Statuses of Filed Patents	69
TABLE 4.6: Recently Granted Notable Exosome Patents	69
TABLE 4.7: Examples of Exosome Patents Licensed.....	71
TABLE 4.8: Number of Patents Held by Select Exosome Companies	71
TABLE 5.1: Exosome-Based Clinical Trials by Country	76
TABLE 5.2: Exosome Study Phases	77
TABLE 5.3: Funding for Clinical Trials.....	78
TABLE 5.4: Examples of Industry Sponsored Clinical Trials	78
TABLE 5.5: Select Clinical Trials Evaluating Exosomes as Cell-Free Therapeutics	81
TABLE 5.6: Select Clinical Trials Evaluating Exosomes as Disease Diagnostics	82
TABLE 5.7: Select Clinical Trials Evaluating Exosomes as Drug Delivery Vehicles	83
TABLE 6.1: Venture Capital Funding Mobilized by Exosome Companies, 2023- June 2026.....	85
TABLE 6.2: Partnership Deals in Exosome Sector, 2023-June 2026	89
TABLE 6.3: Acquisition Deals in Exosome Space, 2023-June 2026	93

TABLE 6.4: Licensing Deals in Exosome Space, 2023-June 2026	95
TABLE 7.1: Key Isolation and Purification Technologies	100
TABLE 7.2: Top Ten Widely Utilized Exosome Isolation & Purification Kits	107
TABLE 8.1: Key Technologies & Methods in Upstream Processing of Exosomes	108
TABLE 8.2: Market-Leading Stirred-Tank Bioreactors	109
TABLE 9.1: Key Technologies for Exosome Clarification	120
TABLE 9.2: Key Technologies Involved in Concentration & Purification	121
TABLE 11.1: Companies with the Expertise for Exosome Engineering	133
TABLE 11.1: Companies Developing Exosomes by Endogenous Loading	134
TABLE 11.2: Companies Developing Exosomes by Exogenous Loading	135
TABLE 11.3: Molecules attached to Exosomes for Surface Modifications	137
TABLE 11.4: Technologies for Exogenous Internal Loading of Exosomes	138
TABLE 11.5: Therapeutics Loaded into Exosomes.....	141
TABLE 11.6: Companies Developing Drug-Loaded Exosomes.....	141
TABLE 11.7: Drug-Loaded Exosomes in the Ongoing Clinical Trials	142
TABLE 11.8: Preclinical Studies using Drug-Loaded Exosomes	143
TABLE 12.1: Prominent Commercial Firms Developing Exosome Therapeutics	145
TABLE 12.2: Development Timeline for Deramiciocel.....	147
TABLE 12.3: Core Therapeutic Exosome Platforms & Technologies	149
TABLE 13.1: Cost of Developing an Exosome-Based Diagnostic Test	162
TABLE 13.2: Companies Developing Exosome-Based Diagnostics for Lung Cancer.....	165
TABLE 13.3: Companies Developing Exosome-Based Diagnostics for Pancreatic Cancer	165
TABLE 13.4: Companies Developing Exosome-Based Diagnostics for Ovarian Cancer.....	166
TABLE 13.5: Companies Developing Exosome Diagnostics for Cardiovascular Diseases.....	167
TABLE 13.6: Companies Developing Exosome Diagnostics for Urology Indications	167
TABLE 13.7: Companies Developing Exosome Diagnostics for Organ Transplantation.....	168
TABLE 13.8: Companies Developing Exosome-Based Diagnostics for Pregnancy	169
TABLE 13.9: Exosome Diagnostics Approaching Market Readiness	169
TABLE 14.1: Specific Applications of Exosomes in Medical Aesthetics	171
TABLE 14.2: Regenerative Processes Initiated by Exosome-based Anti-Aging Products	172
TABLE 14.3: Professional & Clinical-Grade Aesthetic Exosome Products.....	173
TABLE 14.4: Popular At-Home "Exosome-Inspired" Skincare Products	173
TABLE 14.5: Exosome-Based Hair Regeneration Products	174
TABLE 14.6: Popular Exosome-Based Scar Reduction Products	175
TABLE 14.7: Exosome-Based Pigmentation Regulation Products	176
TABLE 14.8: Exosome-Based Post-Procedure Recovery Products	176
TABLE 14.9: Sources of Exosomes for Medical Aesthetic Companies	178
TABLE 15.1: Market Leaders in Exosome Research Products	185
TABLE 15.2: Estimated Market for Exosome Research Products, 2026-2034.....	188
TABLE 15.3: Leading Market Players in Exosome Development	190
TABLE 15.4: Leading Market Players in Exosome Manufacturing Services	191
TABLE 15.5: Market for Exosome Development & Manufacturing Services, 2026-2035.....	193
TABLE 15.6: Global Exosome Diagnostics Market, 2026-2034.....	197
TABLE 15.7: Global Market for Exosome-Based Aesthetics by Product Type, 2026-2034.....	200
TABLE 15.8: Global Market for Exosome-Based Aesthetics by Geography, 2026-2034	201
TABLE 15.9: Global Market for Ready-To-Use Exosomes, 2026-2034.....	210
TABLE 15.10 The Overall Global Market for Exosome-Based Products	213
TABLE 16.1: Leading Companies in Exosome-Based Therapeutics Sector	216
TABLE 16.2: Leading Companies in Exosome-Based Diagnostics Sector.....	217
TABLE 16.3: Leading Companies in Exosome-Based Research Tools	217
TABLE 16.4: CROs Offering Custom Services	218
TABLE 16.5: Leading Companies in Exosome-Based Aesthetics	218
TABLE 16.6: Aegle Therapeutics' Clinical Pipeline	222
TABLE 16.7: AGS Therapeutics' Clinical Focus	224
TABLE 16.8: Aruna Bio's Clinical Programs	230
TABLE 16.9: Capricor Therapeutics' Clinical Programs.....	242

TABLE 16.10: Ciloa's Clinical Programs	246
TABLE 16.11: ConveyXO's Therapeutic Pipeline	249
TABLE 16.12: Direct Biologics' Clinical Pipeline	261
TABLE 16.13: EVerZom's Clinical Pipeline	270
TABLE 16.14: Evox Therapeutics' Clinical Pipeline	275
TABLE 16.15: EV Therapeutics' Clinical Programs	276
TABLE 16.16: EXO Biologics' Clinical Programs	278
TABLE 16.17: Exogenus Therapeutics' Clinical Programs	282
TABLE 16.18: INOVIQ's Clinical Programs.....	310

About BioInformant:

Founded in 2006, BioInformant is the world's first and only market research firm to specialize in the stem cell industry. Headquartered near Washington, DC, to be situated near the U.S. FDA, NIH, Capitol Hill, and the Maryland Biotech Corridor, BioInformant has collected 20+ years of historical data on the stem cell industry, providing a robust and unusual foundation on which to base its market research.

The quality of this report would not be possible without the past 20+ years of following the stem cell industry and developing proprietary datasets (to which AI does not have access). These insights exist because they are built on nearly two decades of granular tracking, industry interviews, and daily monitoring. In addition to leveraging an experienced team of analysts, BioInformant has unparalleled access to key opinion leaders (KOLs) from across the stem cell sector.

To date, BioInformant research has been cited by the *Wall Street Journal* and *Vogue Magazine*, as well as quoted by Tony Robbins in his best-selling book, *LifeForce*.

BioInformant operates the world's largest stem cell industry news site, attracting nearly a million readers per year.

Serving Fortune 500 leaders that include GE Healthcare, Pfizer, and Goldman Sachs, BioInformant is your global leader in stem cell industry data.

